The purpose of this study was to examine whether the social interaction can affect vection strength. We compared the strength of self-motion perception (vection) with and without an audience (two people in addition to the participant) present during stimulus presentation. We presented the optical flow (dots’ expansion) for 40 seconds and obtained vection duration and latency and we also obtained the subjective strength of vection via magnitude estimation. We found that vection was inhibited by the presence of an audience. We speculate that audience presence might distract the attention of participants from the vection, depriving them of the attentional resources inhibited vection.

The mixture consisted of benzotriazole (BTA), chitosan (CTS), polyacrylic acid and zinc salt has been investigated as a corrosion and scale inhibitor of A3 carbon steel in cooling water. The scale and corrosion inhibition efficiency was evaluated by static anti-scaling teat together with rotary coupon test. Compared with the phosphorus corrosion and scale inhibitor, the corrosion inhibition rate and scale inhibition rate of it increased respectively by 2.51% and 1.16%. As the corrosion and scale inhibitor is phosphate-free, it won’t cause eutrophication, considering the product performance and environmental influence, the phosphate-free corrosion and scale inhibitor is superior to the traditional one.

Advanced glycation end products (AGEs) react non-enzymatically with tissue proteins to form irreversible structures involved in atherosclerosis, nephropathy, retinopathy, neuropathy, and wound healing. Studies on AGE-inhibitors have demonstrated possible prevention of diabetes complications. The present open label study was conducted on aminoguanidine (AGu), an inhibitor of AGE-formation, to examine potential effects on wound healing in diabetes type 2-like db/db mice during 5 - 6 weeks. The animals were divided into 4 groups: AGu from the day of wounding (day 0) topically and/or systemically in drinking water (1 g/L; group 1, n = 13); AGu 1 g/L in drinking water from 7 weeks prior to day 0 (group 2, n = 21); AGu 5 g/L in drinking water from 9 - 11 weeks prior to day 0 (group 3, n = 6); placebo controls (group 4, n = 8). Results: Glycated hemoglobin (A1C) was significantly lower in group 3 compared to the other groups (P < 0.05). Percentage change in A1C and body weight from baseline to the end of the experiment were both related to the AGu doses (1 or 5 g/L; A1C-change, P